Additionally, disease progression in over 30% of these cases is attributed to resistance to hormonal therapy.[26] This highlights the importance of maintenance of hormonal receptors in the explants for a considerable duration (>3 days) to identify new targets and study patient‐dependent resistance mechanisms.[26] In our study, we showed the presence of ER and PR markers in ER+/PR+ PDEs (BC‐1 and BC‐5) for 2 weeks and 1 week respectively. The gene discussed is NR4A1; the disease is breast cancer.